Raloxifene is not indicated for premenopausal use, and is not effective in reducing hot flashes or flushes associated with estrogen deficiency. In fact, in some symptomatic and asymptomatic patients, hot flashes may occur upon beginning raloxifene therapy. The primary reason women seek medical treatment at the time of menopause is for relief of vasomotor symptoms, such as hot flashes, night sweats, and vaginal dryness, all of which can affect a woman's sense of well-being and sexual intimacy. The effects of raloxifene on fracture risk are not yet known. Lipid-Lowering Heart disease is the number one cause of death in postmenopausal women.
Observational data suggest a potential lipid-lowering effect with hormone replacement therapy.
Some studies have suggested a possible increased incidence of breast cancer in those women on estrogen therapy taking higher doses for prolonged periods of time. The majority of studies, however, have not shown an association with the usual doses used for estrogen replacement therapy. While Premarin has been shown to positively impact osteoporosis and vasomotor symptoms, additional research is being conducted to study its possible protective effects on the heart and brain. Premarin is the most prescribed drug in the United States. It has been available for 56 years, and has been studied in over 3,000 scientific trials.